Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 28 results found. Search for [ pfizer seeks India approval ]

Results 1 to 21 of 28
Rashi Bisaria
New Delhi, March 11, 2021
Pfizer wants to make vaccine in India; seeks assurance on faster clearance, export freedom Pfizer Inc has told the Indian government it wants to produce its coronavirus vaccine locally if assured of faster regulatory clearance and freedom on pricing and exports. The U.S. company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept its vaccine, developed with German...


Reuters
March 10, 2021
The US company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept its vaccine, developed with Germany's BioNTech SE, out of one of the world's biggest drug markets


BusinessToday.In
March 5, 2021
Biden administration recently decided to enforce Defence Production Act, which allowed it to boost vaccine production by blocking export of raw material supplies to other countries


Reuters
January 29, 2021
Serum expected a decision on an Indian trial of Novavax's vaccine soon, Chief Executive Adar Poonawalla said, hours after the US company reported the efficacy data


Reuters
January 22, 2021
Details on the size of the deal or the price per dose COVAX would pay were not immediately clear, but the sources said the allotment would likely be relatively small


BusinessToday.In
January 2, 2021
Covishield DCGI approval: Pune-based Serum Institute will have to provide safety, efficacy and immunogenicity data from the ongoing clinical trials in India and globally


BusinessToday.In
January 1, 2021
Covishield has become the first coronavirus vaccine to receive a regulatory nod in India. Now, Drug Controller General of India (DCGI) will take a final call on rolling out the inoculation


PTI
January 1, 2021
The World Health Organisation (WHO) said its review found the Pfizer-BioNTech vaccine met the must-have criteria for safety and efficacy set out by it


BusinessToday.In
December 23, 2020
DCGI gives a green signal to SII, India will be the first nation to approve the Oxford vaccine under emergency use authorisation; British health regulator is still evaluating Oxford-AstraZeneca data


BusinessToday.In
December 19, 2020
SII had earlier said its vaccine candidate showed 90 per cent efficacy rate at a full dose plus a half dose regimen, while a 62 per cent efficacy rate at full two-dose regimen


BusinessToday.In
December 13, 2020
As of December 11, Mexico remains the fourth worst-affected country by the pandemic in the world.


BusinessToday.In
December 13, 2020
David Prior says next three months are going to be extremely difficult and the world is pinning hopes on vaccine; Serum Institute also hopes to get approval for emergency use in India soon after nod in the UK


BusinessToday.In
December 12, 2020
US President Donald Trump says: \"We've delivered a safe and effective vaccine in just 9 months. This is one of the greatest scientific accomplishments in history\"


BusinessToday.In
December 11, 2020
The regulatory approval in the UK is crucial to strengthen SII's application seeking emergency use authorisation in India because the proposal here refers to trials being conducted in the UK and Brazil


PB Jayakumar
December 10, 2020
Though Pfizer India says it remains committed to advance dialogue with Indian government to make the vaccine available for use, experts believe it will be difficult for its parent to supply adequate quantities of the vaccine


BusinessToday.In
December 10, 2020
The Subject Expert Committee (SEC), a government panel tasked with vetting coronavirus vaccines, has asked Bharat Biotech and Serum Institute of India (SII) to submit updated country-specific trial data of their vaccine candidates Covaxin and Covishield


BusinessToday.In
December 9, 2020
Several experts have raised questions about Bharat Biotech applying for emergency usage as Covaxin is still going through an efficacy trial. However, the ICMR has backed Bharat Biotech's move


Vivek Punj
December 9, 2020
Medical journal Lancet pointed out that surprisingly the COVID-19 vaccine candidate was 90 per cent effective when a low dose was followed by a full dose


BusinessToday.In
December 7, 2020
On December 2, the UK became the first nation to approve Pfizer-BioNTech vaccine against COVID-19 for emergency use; Bahrain has also approved vaccine candidate 'BNT162b2'. India decision on vaccine could come this week


BusinessToday.In
December 7, 2020
As per the Indian Council of Medical Research (ICMR), Serum Institute has manufactured four crore doses of the vaccine under the at-risk manufacturing and stockpiling licence obtained from the DCGI


PAGES 1 OF 2  12